




RealRate

PHARMACEUTICAL 2020

BioXcel Therapeutics Inc.
Rank 202 of 358



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of BioXcel Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BioXcel Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 74% points. The greatest weakness of BioXcel Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 58%, being 22% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	34,107
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,468
Liabilities, Non-Current	1,029
Other Assets	1,244
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	633
Other Revenues	0
Property and Equipment	1,041
Research and Development	25,797
Selling, General and Administrative Expense	7,804

Output Variable	Value in 1000 USD
Assets	36,392
Liabilities	9,497
Expenses	33,601
Revenues	0
Stockholders Equity	26,895
Net Income	-32,968
Comprehensive Net Income	-32,968
Economic Capital Ratio	58%